Dobataf-3 Tablet

Description

Generic Name:

Dobataf-3 PeP Tablet contains a combination of antiretroviral drugs used for post-exposure prophylaxis (PeP) to prevent HIV infection after potential exposure.

 

Composition:

Each Dobataf-3 PeP Tablet consists of:

• Tenofovir Disoproxil Fumarate (TDF) – Nucleotide reverse transcriptase inhibitor (NRTI) that blocks HIV replication.
• Lamivudine (3TC) – Nucleoside reverse transcriptase inhibitor (NRTI) that prevents HIV from multiplying.
• Dolutegravir (DTG) – Integrase strand transfer inhibitor (INSTI) that stops viral DNA integration into human cells.

 

Indication:

Dobataf-3 PeP Tablet is indicated for:

• Post-Exposure Prophylaxis (PeP) – Preventing HIV infection after potential exposure.
• Used in healthcare workers and individuals with accidental exposure to HIV.
• May be used as part of combination antiretroviral therapy (ART) for HIV treatment.

 

Storage Instructions:

• Store at room temperature (15-30°C) in a dry place.
• Keep away from moisture and direct sunlight.
• Keep out of reach of children.
• Do not use beyond its expiry date.

 

Uses of the Medicine:

• Prevents HIV infection if taken within 72 hours of exposure.
• Reduces the risk of HIV transmission in high-risk individuals.
• Supports long-term HIV treatment in combination therapy.

 

Benefits of the Medicine:

• Provides effective post-exposure HIV prevention.
• Helps stop HIV replication before it establishes infection.
• Reduces the risk of occupational exposure to HIV in healthcare settings.
• Enhances immune system protection against the virus.

 

Side Effects:

Common side effects include:

• Nausea and vomiting
• Diarrhea
• Fatigue and weakness
• Headache and dizziness
• Insomnia or sleep disturbances

 

Serious Side Effects Include:

• Liver toxicity (yellowing of skin/eyes, dark urine, severe abdominal pain).
• Severe allergic reactions (rash, swelling, breathing difficulties).
• Lactic acidosis (muscle pain, breathing difficulties, severe weakness).
• Immune reconstitution syndrome (worsening of pre-existing infections).
• Depression or mood changes.

 

How to Use the Medicine:

• Take one tablet once daily, or as prescribed by your doctor.
• Start PeP treatment within 72 hours of exposure for maximum effectiveness.
• Continue taking the medicine for 28 days without interruption.
• Can be taken with or without food.
• Swallow the tablet whole with water. Do not crush or chew.

 

How the Medicine Works:

Dobataf-3 PeP Tablet contains Tenofovir, Lamivudine, and Dolutegravir, which work together to block HIV replication at multiple stages. The combination prevents the virus from integrating into human cells, thereby stopping the establishment of infection.

What If You Forget to Take the Medicine?

• Take the missed dose as soon as you remember.
• If it is close to the next scheduled dose, skip the missed dose and continue as usual.
• Do not take a double dose to make up for a missed one.
• Missing doses reduces effectiveness, so ensure strict adherence.

 

Quick Tips:

• Start PeP as soon as possible, ideally within 72 hours of exposure.
• Take the medicine at the same time daily for best results.
• Do not stop taking it before completing the full 28-day course.
• Avoid alcohol, as it may increase side effects.
• Use safe sex practices and precautionary measures even while on PeP.
• Regular blood tests are required to monitor health conditions.

 

Safety Advice

 

Caution is advised when consuming alcohol with Dobataf-3 Tablet. Please consult your doctor for guidance.

 

Dobataf-3 Tablet is unsafe to use during pregnancy due to potential harm to the developing baby. It may only be prescribed in life-threatening situations where benefits outweigh the risks. Please consult your doctor.

 

There is insufficient information on the use of Dobataf-3 Tablet while breastfeeding. Please consult your doctor before use.

 

It is uncertain whether Dobataf-3 Tablet affects your ability to drive. Avoid driving if you experience drowsiness, dizziness, or reduced alertness.

 

Limited data is available on the safety of Dobataf-3 Tablet in patients with kidney disease. Dose adjustments may be necessary. Please consult your doctor.

 

Dobataf-3 Tablet should be used with caution in patients with liver disease. Dose adjustments may be required based on the severity of the condition. Please consult your doctor.

 

 

FAQs:

Q: Can Dobataf-3 PeP cure HIV?
A: No, it helps prevent HIV infection if taken within 72 hours of exposure but does not cure the disease.

 

Q: Can I take this medicine after 72 hours of exposure?
A: PeP is most effective within 72 hours. Delayed use reduces its success rate significantly.

 

Q: Does Dobataf-3 PeP have serious side effects?
A: It may cause liver toxicity, lactic acidosis, and immune reconstitution syndrome in rare cases.

 

Q: Can I stop taking PeP if I feel fine?
A: No, complete the full 28-day course for maximum protection against HIV infection.

 

Q: Can pregnant women take this medicine?
A: Consult a doctor before use. PeP may be used if the benefits outweigh the risks.

 

 

Related Lab Tests:

• HIV Antibody Test
• HIV Viral Load Test
• Liver Function Test (LFT)
• Kidney Function Test (KFT)
• Complete Blood Count (CBC)

Additional information

Weight	100 g
Composition	Dolutegravir 50 mg/Tenofovir alfanamide 25 mg/Emtricitabin 200mg
Pack	30PACK
Manufacturer	AUROBINDO